---
document_datetime: 2025-11-21 15:22:41
document_pages: 3
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/segluromet-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: segluromet-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 4.5035263
conversion_datetime: 2025-12-28 03:26:09.315961
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Segluromet

Procedural steps taken and scientific information after the authorisation*

*Due to the Agency' s update of its procedure management systems, an additional document, reflecting the historical lifecycle may be available in the 'Assessmenthistory'section.Forthe completeproduct lifecycleprocedures,you mayneedtoalsorefertoEPAR-Proceduralsteps taken andscientific informationafterauthorisation(archive).

| Applicationnumber   | Scope                                  | Opinion/ Notification 1 issued on   | Commission Decision IssuedÂ²/ amendedon   | Product Information affected3   | Summary   |
|---------------------|----------------------------------------|-------------------------------------|------------------------------------------|---------------------------------|-----------|
| Article 61(3) /     | Notification acc.Article61(3)-Accepted | 21/11/2025                          |                                          | PL                              |           |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| EMA/N/0000312917                      | Update of the package leaflet with revised contactdetailsoflocalrepresentatives.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |            |     |             |
|---------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-------------|
| Variation type IA / EMA/VR/0000289536 | B.II.b.2 Change to importer,batch release arrangements and quality control testing of the finished product - B.I1.b.2.a Replacementoradditionofasitewhere batch control/testing takesplace-Accepted                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | 20/08/2025 | N/A |             |
| VariationtypeIB/ EMA/VR/0000262413    | C.1.3Change(s)in theSummary of Product Characteristics,Labelling orPackageLeaflet of human medicinalproducts intended to implement the outcome of a procedure concerningPSURorPASS,orthe outcome of theassessmentdonebythecompetent authority under Articles 45 or 46 of Regulation1901/2006-C.1.3.z Implementationofwording agreedbythe competent authority + QRD update - Accepted Toupdatesection 4.4of theSmPC to introduce a warning on aggravation of MELAS(Mitochondrial Encephalopathywith LacticAcidosis,and Stroke-like episodes) syndrome and MIDD (Maternal inherited diabetes and deafness) in patients taking metformin withknown mitochondrial diseases following the outcome of PSUSA/00002001/202404.The Package | 02/05/2025 |     | SmPC and PL |

<div style=\"page-break-after: always\"></div>

| the MAH has updated the details of the Local Representatives for Lithuania/Denmark/Germany/Estonia/Norwa y/Spain/Iceland/Sweden/Latvia and updated to thelatestQRD template.   |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|